AstraZeneca and Daiichi Sankyo shared the pooled analysis behind the refiling of their TROP2 antibody-drug conjugate (ADC) ...

Daiichi Sankyo has announced the dosage of the first subject in the randomised Phase III QuANTUM-Wild trial of oral Vanflyta ...

In tandem with Enhertu’s inclusion in China’s national insurance program, Daiichi Sankyo is planting a foothold in local ...

Developed alongside AstraZeneca, the breakthrough designation comes following early pooled results from two ongoing trials ...

Daiichi Sankyo invests $150 million to establish a new antibody-drug conjugate manufacturing facility in Shanghai by 2030, ...

AstraZeneca and Daiichi Sankyo have shared the data they believe can secure approval for datopotamab deruxtecan (Dato-DXd) at ...

At the conference, AstraZeneca and Daiichi Sankyo will present their case for Dato-DXd in NSCLC, while BioNTech and Merus ...

Datopotamab deruxtecan has been granted Breakthrough Therapy Designation, or BTD, in the U.S. for the treatment of adult patients with locally ...

Daiichi Sankyo begins patient dosing in QuANTUM-Wild phase 3 trial of Vanflyta in newly diagnosed FLT3-ITD negative AML: Tokyo Thursday, December 12, 2024, 12:00 Hrs [IST] The fir ...

Elevation Oncology has tapped Lonza’s Synaffix to support the expansion of its pipeline, agreeing to pay up to $368 million ...

Daiichi Sankyo Company is making significant strides in the pharmaceutical industry, evidenced by its financial growth and strategic collaborations, such as with Merck on MK-6070. The company is set ...